Six-year multi-centre, observational, post-marketing surveillance of the safety of the HPV-16/18 AS04-adjuvanted vaccine in women aged 10-25 years in Korea.

Chul-Jung KimRok SongJing ChenFernanda Tavares Da SilvaKusuma B GopalaJoon Hyung KimDan BiJong Sup Park

Published in: Pharmacoepidemiology and drug safety (2017)

This is the first post-marketing surveillance study in Korea that provides 6-year safety data for HPV-16/18 AS04-adjuvanted vaccine. The vaccine showed an acceptable safety profile and favourable benefit/risk ratio when given to women aged 10-25 years in Korea. © 2017 The Authors. Pharmacoepidemiology & Drug Safety Published by John Wiley & Sons Ltd.

Keyphrases

public health
polycystic ovary syndrome
cervical cancer screening
high grade
randomized controlled trial
systematic review
pregnancy outcomes
adipose tissue
metabolic syndrome
big data
machine learning
electronic health record
artificial intelligence
drug induced
meta analyses
data analysis